217 related articles for article (PubMed ID: 28783865)
1. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
[TBL] [Abstract][Full Text] [Related]
2. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
Gupta N; Hanley MJ; Venkatakrishnan K; Wang B; Sharma S; Bessudo A; Hui AM; Nemunaitis J
J Clin Pharmacol; 2016 Oct; 56(10):1288-95. PubMed ID: 26872892
[TBL] [Abstract][Full Text] [Related]
3. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
[TBL] [Abstract][Full Text] [Related]
5. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
Kumar SK; Bensinger WI; Zimmerman TM; Reeder CB; Berenson JR; Berg D; Hui AM; Gupta N; Di Bacco A; Yu J; Shou Y; Niesvizky R
Blood; 2014 Aug; 124(7):1047-55. PubMed ID: 24904120
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
[TBL] [Abstract][Full Text] [Related]
10. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Gupta N; Hanley MJ; Venkatakrishnan K; Perez R; Norris RE; Nemunaitis J; Yang H; Qian MG; Falchook G; Labotka R; Fu S
Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
Machida M; Fukunaga S; Hara T
Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
16. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
17. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
[TBL] [Abstract][Full Text] [Related]
18. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
Gupta N; Huh Y; Hutmacher MM; Ottinger S; Hui AM; Venkatakrishnan K
Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
[TBL] [Abstract][Full Text] [Related]
20. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
